Faculty Profiles - ARIMA, Hiroshi

Papers - ARIMA, Hiroshi

Division display 1 - 20 of about 282 ／ All the affair displays >>

Voluntary exercise suppresses inflammation and improves insulin resistance in the arcuate nucleus and ventral tegmental area in mice on a high-fat diet. International journal

Tomoyuki Sasaki, Mariko Sugiyama, Mitsuhiro Kuno, Takashi Miyata, Tomoko Kobayashi, Yoshinori Yasuda, Takeshi Onoue, Hiroshi Takagi, Daisuke Hagiwara, Shintaro Iwama, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

Physiology & behavior Vol. 287 page： 114703 - 114703 2024.12

Language：English Publishing type：Research paper (scientific journal)

A high-fat diet (HFD) causes inflammation with an increase in microglial activity in the hypothalamic arcuate nucleus (ARC) and ventral tegmental area (VTA), resulting in insulin resistance in both regions. This leads to a deterioration in glucose and energy metabolism. The effect of voluntary exercise on HFD-induced inflammation in the central nervous system (CNS) remains unclear. To clarify the effects of voluntary exercise on the CNS, 8-week-old male C57BL6 mice were fed a chow diet (CHD) or HFD for 4 weeks; each group was further divided into running exercise (EX+) on a wheel and no exercise (EX-) groups. The expression of the inflammatory cytokine, tumor necrosis factor alpha (TNFα), in the ARC and VTA was significantly increased in the HFD/EX- group, with an increase of microglial activity noted, compared to the CHD/EX- group. The expression of TNFα was significantly suppressed, with a decrease of microglial activity, in the HFD/EX+ compared to HFD/EX- group. Insulin resistance in the ARC and VTA was improved with the suppression of TNFα expression. The HFD/EX- group showed significant weight gain and impaired glucose metabolism compared to the CHD/EX- group. The HFD/EX+ group showed an improvement in glucose and energy metabolism compared to the HFD/EX- group. In addition, voluntary wheel running suppressed HFD-induced inflammation in the ARC, with a decrease in microglial activity observed independently of weight changes. Our data suggest that voluntary exercise prevents obesity and improves glucose metabolism by suppressing inflammation in the ARC and VTA under HFD conditions.

DOI： 10.1016/j.physbeh.2024.114703

Web of Science

PubMed

Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

Arima, H; Cheetham, T; Christ-Crain, M; Cooper, D; Drummond, J; Gurnell, M; Levy, M; McCormack, A; Newell-Price, J; Verbalis, JG; Wass, J

CLINICAL ENDOCRINOLOGY Vol. 101 ( 5 ) page： 443 - 445 2024.11

Internet of things-based approach for glycemic control in people with type 2 diabetes: A randomized controlled trial Invited Reviewed

Bouchi, R; Izumi, K; Ishizuka, N; Uemura, Y; Ohtsu, H; Miyo, K; Tanaka, S; Satoh-Asahara, N; Hara, K; Odawara, M; Kusunoki, Y; Koyama, H; Onoue, T; Arima, H; Tsushita, K; Watada, H; Kadowaki, T; Ueki, K

JOURNAL OF DIABETES INVESTIGATION Vol. 15 ( 9 ) page： 1287 - 1296 2024.9

Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study. Reviewed

Takayuki Okuji, Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Masaaki Ito, Ayana Yamagami, Masahiko Ando, Tetsunari Hase, Hirofumi Shibata, Takahiro Hatta, Xin Zhou, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yuichi Ando, Naozumi Hashimoto, Hiroshi Arima

Nagoya journal of medical science Vol. 86 ( 3 ) page： 452 - 463 2024.8

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

The presence of anti-thyroid antibodies (ATAs) is a biomarker for the development of thyroid dysfunction induced by anti-programmed cell death-1 antibodies (PD-1-Abs). While patients with thyroid dysfunction reportedly showed better overall survival (OS), it remains unknown if ATAs at baseline can predict OS. Therefore, in this study, we examined the association of ATAs at baseline with OS in non-small cell lung cancer (NSCLC) patients with different levels of programmed cell death-1 ligand 1 (PD-L1) positivity associated with PD-1-Ab treatment efficacy. A total of 81 NSCLC patients treated with PD-1-Abs were evaluated for ATAs at baseline and prospectively for OS. Among the 81 patients, 49 and 32 patients had ≥50% (group A) and <50% (group B) PD-L1 positivity, respectively. Median OS did not differ significantly between patients with (n = 13) and without (n = 36) ATAs at baseline in group A. In contrast, median OS was significantly longer in patients with (n = 10) versus without (n = 22) ATAs at baseline in group B (not reached vs 378 days, respectively; 95% CI, 182 to 574 days, p = 0.049). These findings suggest that the presence of ATAs at baseline is a biomarker to predict better treatment efficacy of PD-1-Abs in NSCLC patients with low PD-L1 positivity, while the difference in OS in those with high PD-L1 positivity may be masked by increased tumor expression of PD-L1.

DOI： 10.18999/nagjms.86.3.452

Web of Science

PubMed

Hyperthyroidism Due to Functioning Metastatic Bone Lesions of Follicular Thyroid Carcinoma Treated With Lenvatinib. Reviewed

Kobayashi T, Iwama S, Suzuki K, Arima H

JCEM case reports Vol. 2 ( 7 ) page： luae139 2024.7

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study Reviewed

Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

CANCER IMMUNOLOGY IMMUNOTHERAPY Vol. 73 ( 8 ) page： 146 2024.6

Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report Reviewed

Kato, S; Sakamoto, K; Sato, T; Kobayashi, T; Shindo, Y; Morise, M; Iwama, S; Arima, H; Ishii, M

RESPIRATORY INVESTIGATION Vol. 62 ( 2 ) page： 313 - 316 2024.3

Simplified drug efficacy evaluation system for vasopressin neurodegenerative disease using mouse disease-specific induced pluripotent stem cells Reviewed

Tsutomu Miwata, Hidetaka Suga, Kazuki Mitsumoto, Jun Zhang, Yoshimasa Hamada, Mayu Sakakibara, Mika Soen, Hajime Ozaki, Tomoyoshi Asano, Takashi Miyata, Yohei Kawaguchi, Yoshinori Yasuda, Tomoko Kobayashi, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara, Shintaro Iwama, Seiichi Oyadomari, Hiroshi Arima

Peptides Vol. 173 page： 171151 - 171151 2024.3

Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study. International journal

Tomoko Handa, Takeshi Onoue, Tomoko Kobayashi, Ryutaro Maeda, Keigo Mizutani, Ayana Yamagami, Tamaki Kinoshita, Yoshinori Yasuda, Shintaro Iwama, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yoshinori Azuma, Takatoshi Kasai, Shuko Yoshioka, Yachiyo Kuwatsuka, Hiroshi Arima

JMIR diabetes Vol. 9 page： e48019 2024.1

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: In recent years, technologies promoting the digitization of self-monitoring of blood glucose (SMBG) records including app-cloud cooperation systems have emerged. Studies combining these technological interventions with support from remote health care professionals have reported improvements in glycemic control. OBJECTIVE: To assess the use of an app-cloud cooperation system linked with SMBG devices in clinical settings, we evaluated its effects on outpatient management of diabetes without remote health care professional support. METHODS: In this multicenter, open-label, and single-armed prospective study, 48 patients with diabetes (including type 1 and type 2) at 3 hospitals in Japan treated with insulin or glucagon-like peptide 1 receptor agonists and performing SMBG used the app-cloud cooperation system for 24 weeks. The SMBG data were automatically uploaded to the cloud via the app. The patients could check their data, and their attending physicians reviewed the data through the cloud prior to the patients' regular visits. The primary outcome was changes in glycated hemoglobin (HbA1c) levels. RESULTS: Although HbA1c levels did not significantly change in all patients, the frequency of daily SMBG following applying the system was significantly increased before induction at 12 (0.60 per day, 95% CI 0.19-1.00; P=.002) and 24 weeks (0.43 per day, 95% CI 0.02-0.84; P=.04). In the subset of 21 patients whose antidiabetic medication had not been adjusted during the intervention period, a decrease in HbA1c level was observed at 12 weeks (P=.02); however, this significant change disappeared at 24 weeks (P=.49). The Diabetes Treatment Satisfaction Questionnaire total score and "Q4: convenience" and "Q5: flexibility" scores significantly improved after using the system (all P<.05), and 72% (33/46) patients and 76% (35/46) physicians reported that the app-cloud cooperation system helped them adjust insulin doses. CONCLUSIONS: The digitization of SMBG records and sharing of the data by patients and attending physicians during face-to-face visits improved self-management in patients with diabetes. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) jRCTs042190057; https://jrct.niph.go.jp/en-latest-detail/jRCTs042190057.

DOI： 10.2196/48019

PubMed

The multifaceted role of ATF4 in regulating glucose-stimulated insulin secretion (vol 611, pg 165, 2022) Reviewed

Sobajima, M; Miyake, M; Hamada, Y; Tsugawa, K; Oyadomari, M; Inoue, R; Shirakawa, J; Arima, H; Oyadomari, S

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Vol. 692 page： 149412 2024.1

Impact of coronavirus disease 2019 on medical practice in endocrine and metabolic diseases in Japan: a nationwide surveillance study conducted by the Japan Endocrine Society Reviewed

Manaka, K; Kato, S; Sakamoto, R; Yamakage, H; Uema, T; Kawai, S; Shibata, M; Hiratsuka, I; Nakachi, S; Onoue, T; Tsuchiya, T; Fukui, M; Hashimoto, K; Suzuki, A; Makita, N; Ogawa, Y; Arima, H; Satoh-Asahara, N; Masuzaki, H

ENDOCRINE JOURNAL Vol. 71 ( 5 ) page： 499 - 514 2024

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events Reviewed

Kobayashi, T; Iwama, S; Arima, H

ENDOCRINE JOURNAL Vol. 71 ( 1 ) page： 23 - 29 2024

A machine learning approach for predicting treatment response of hyponatremia Reviewed

Kinoshita, T; Oyama, S; Hagiwara, D; Azuma, Y; Arima, H

ENDOCRINE JOURNAL Vol. 71 ( 4 ) page： 345 - 355 2024

A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature Reviewed

Kyo, C; Kobayashi, T; Iwama, S; Kosugi, R; Sawabe, F; Hayafusa, R; Sakai, Y; Ogawa, T; Kotani, M; Inoue, T; Arima, H; Ariyasu, H

ENDOCRINE JOURNAL Vol. 71 ( 8 ) page： 799 - 807 2024

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade Reviewed

Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

Endocrine Journal Vol. 71 ( 5 ) page： 515 - 526 2024

Improved glycemic control after the use of flash glucose monitoring accompanied by improved treatment satisfaction in patients with non-insulin-treated type 2 diabetes: A post-hoc analysis of a randomized controlled trial. Reviewed International journal

Ayaka Hayase, Takeshi Onoue, Tomoko Kobayashi, Eri Wada, Tomoko Handa, Tamaki Kinoshita, Ayana Yamagami, Yoshinori Yasuda, Shintaro Iwama, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yachiyo Kuwatsuka, Masahiko Ando, Motomitsu Goto, Hiroshi Arima

Primary care diabetes Vol. 17 ( 6 ) page： 575 - 580 2023.12

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

AIMS: In our previously reported randomized controlled trial in patients with noninsulin-treated type 2 diabetes, the use of flash glucose monitoring (FGM) improved glycated hemoglobin (HbA1c), and the improvement was sustained after the cessation of glucose monitoring. In this post-hoc analysis, we examined data from our trial to identify the factors that influenced FGM efficacy. METHODS: We analyzed data for 48 of 49 participants of the FGM group who completed the trial to clarify the changes in various parameters and factors related to HbA1c improvement with the use of FGM. RESULTS: Analyses of the FGM data during the 12-week FGM provision period showed that the weekly mean blood glucose levels considerably decreased as early as at 1 week compared with the baseline values, and this decline continued for 12 weeks. An enhancement in the Diabetes Treatment Satisfaction Questionnaire regarding "willingness to continue the current treatment" score was significantly associated with the improvement in HbA1c at 12 (p = 0.009) and 24 weeks (p = 0.012). CONCLUSIONS: Glycemic control was improved soon after FGM initiation, accompanied by improved satisfaction with continuation of the current treatment in patients with noninsulin-treated type 2 diabetes.

DOI： 10.1016/j.pcd.2023.09.009

Web of Science

PubMed

Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline. Reviewed International journal

Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima

The Journal of clinical endocrinology and metabolism Vol. 108 ( 10 ) page： E1056 - E1062 2023.9

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

CONTEXT: Positive antithyroglobulin (TgAb) and/or antithyroid peroxidase antibodies (TPOAb) at baseline indicate a high risk of thyroid immune-related adverse events (irAEs) induced by antiprogrammed cell death-1 antibodies (anti-PD-1-Ab). However, whether the positivity patterns of both antibodies are associated with the risk of thyroid irAEs is unknown. OBJECTIVE: The aim of the present study was to clarify the association of the pattern of TgAb and TPOAb positivity at baseline with the risk of thyroid irAEs induced by anti-PD-1-Ab. METHODS: Patients (n = 516) were evaluated for TgAb and TPOAb at baseline and prospectively for thyroid function every 6 weeks for 24 weeks after initiating anti-PD-1-Ab. RESULTS: Fifty-one (9.9%) patients developed thyroid irAEs (thyrotoxicosis in 34, hypothyroidism without prior thyrotoxicosis in 17). Twenty-five patients subsequently developed hypothyroidism following thyrotoxicosis. The cumulative incidence of thyroid irAEs differed among 4 groups classified by the presence of TgAb/TPOAb at baseline (group 1: TgAb-(-)/TPOAb-(-), 4.6% [19/415]; group 2: TgAb-(-)/TPOAb-(+), 15.8% [9/57]; group 3: TgAb-(+)/TPOAb-(-), 42.1% [8/19]; group 4: TgAb-(+)/TPOAb-(+), 60.0% [15/25]) as follows: groups 1 vs 2-4 (P ≤ .001) and groups 2 vs 3 (P = .008) and 4 (P < .001). There were different incidences of thyrotoxicosis (groups 1-4, 3.1%, 5.3%, 31.6%, 48.0%, respectively; P < .001) in groups 1 vs 3 and 4, and groups 2 vs 3 and 4, and of hypothyroidism (groups 1-4: 2.9%, 15.8%, 31.6%, 60.0%, respectively; P < .001) in groups 1 vs 2 to 4, and groups 2 vs 4. CONCLUSION: The risk of thyroid irAEs was affected by the pattern of TgAb and TPOAb positivity at baseline; there were high risks of thyrotoxicosis in patients with TgAb-(+) and of hypothyroidism in patients with TgAb-(+) and those with TPOAb-(+).

DOI： 10.1210/clinem/dgad231

Web of Science

PubMed

Generation and purification of ACTH-secreting hPSC-derived pituitary cells for effective transplantation. International journal

Shiori Taga, Hidetaka Suga, Tokushige Nakano, Atsushi Kuwahara, Naoko Inoshita, Yu Kodani, Hiroshi Nagasaki, Yoshitaka Sato, Yusuke Tsumura, Mayu Sakakibara, Mika Soen, Tsutomu Miwata, Hajime Ozaki, Mayuko Kano, Kenji Watari, Atsushi Ikeda, Mitsugu Yamanaka, Yasuhiko Takahashi, Sachiko Kitamoto, Yohei Kawaguchi, Takashi Miyata, Tomoko Kobayashi, Mariko Sugiyama, Takeshi Onoue, Yoshinori Yasuda, Daisuke Hagiwara, Shintaro Iwama, Yoshitaka Tomigahara, Toru Kimura, Hiroshi Arima

Stem cell reports Vol. 18 ( 8 ) page： 1657 - 1671 2023.8

Language：English Publishing type：Research paper (scientific journal)

Pituitary organoids are promising graft sources for transplantation in treatment of hypopituitarism. Building on development of self-organizing culture to generate pituitary-hypothalamic organoids (PHOs) using human pluripotent stem cells (hPSCs), we established techniques to generate PHOs using feeder-free hPSCs and to purify pituitary cells. The PHOs were uniformly and reliably generated through preconditioning of undifferentiated hPSCs and modulation of Wnt and TGF-β signaling after differentiation. Cell sorting using EpCAM, a pituitary cell-surface marker, successfully purified pituitary cells, reducing off-target cell numbers. EpCAM-expressing purified pituitary cells reaggregated to form three-dimensional pituitary spheres (3D-pituitaries). These exhibited high adrenocorticotropic hormone (ACTH) secretory capacity and responded to both positive and negative regulators. When transplanted into hypopituitary mice, the 3D-pituitaries engrafted, improved ACTH levels, and responded to in vivo stimuli. This method of generating purified pituitary tissue opens new avenues of research for pituitary regenerative medicine.

DOI： 10.1016/j.stemcr.2023.05.002

Web of Science

PubMed

ストレプトゾトシン糖尿病マウスにおける抗PD-1抗体の抗腫瘍効果低下とケモカインの関連

伊藤雅晃, 岩間信太郎, 安田康紀, 井土哲志, 奥地剛之, 山上綾菜, Xin Zhou, 小林朋子, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 3 ) page： 721 - 721 2023.7

線条体ニューロンにおけるPTP1Bは高脂肪食に対する報酬効果を増強する

久納光皓, 坂野僚一, 王思嫻, 佐々木智之, 孫汝楠, 廣瀬友矩, 杉山摩利子, 高木博史, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 321 - 321 2023.5

　 PREV - NEXT 　

<ARIMA, Hiroshi>

Papers - ARIMA, Hiroshi